科研成果: 1.科研项目 (1)国家自然科学青年基金(No.82204315,主持) (2)北欧药学会基金(No.85352,主持) (3)浙江省自然科学基金探索项目(No.LQ22H300003,主持) (4)温州市基础研究项目(No.Y20220196,主持) (5)蓝莓保健品的开发(横向课题,主持) (6)***原料药固态结构研究及质量控制(横向课题,主持) (7)国家重大新药创制专项(No.2019ZX09301-148,参与) 2.所获成果(包括科研成果奖、专利、专著等) 成果转化: 转让1类新药项目1项,金额超过亿元 新药临床批件: 用于治疗糖尿病肾病的1类新药C66胶囊(临床试验通知书编号:2023LP00***) 荣誉: 2022年温州医科大学优秀带教老师 2022年校级先进科研工作者 授权专利: ZL2019108319889一种姜黄素衍生物的晶型I及其制备方法和应用 ZL202010960364X一种化合物及其制备由Flt3/c-Met激酶高表达所引起疾病的药物的应用
ZL202011167212.0 一种沙尔威酮衍生物在药物制备中的应用 ZL2022115805760 一种他达拉非-聚谷氨酸无定形组合物及其制备方法和应用 ZL2022113754660 一种姜黄素衍生物的固体分散体及其制备和应用 ZL2022109500055 一种乙烷-1,2-双(3-芳基丙烯酸酯)类化合物及其在药物制备中的应用 ZL202210632102.X 一种2,6-二苯亚甲基环己酮肟类化合物及其制备方法和应用 ZL2023112281113 一种咪唑吡啶衍生物在制备治疗或预防骨髓增殖性肿瘤药物中的应用 3.发表论文(具有代表性的5篇) (1)Wenqi Wu, Korbinian Löbmann, Thomas Rades, Holger Grohganz. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems. Int. J. Pharm, 2018, 535(1-2): 86~94. ESI高被引论文,引用次数在领域内排名前1%。 (2)Luyan Shen, Xianzhi Liu, Wencheng Wu, Lin Zhou, Guang Liang, Yi Wang, Wenqi Wu. “Aging” in co-amorphous systems: Dissolution decrease and non-negligible dissolution increase during storage without recrystallization. Int. J. Pharm,. 2024, 667:124943. (3)Xianzhi Liu, Luyan Shen, Lin Zhou, Wencheng Wu, Guang Liang, Yunjie Zhao, Wenqi Wu. Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability. Eur. J. Pharm. Biopharm,. 2024, 200:114333. (4)Qiang Huang, Zhiren Zou, Xiaobo Li, Qinwen Xiao, Guang Liang, Wenqi Wu. Poly (amino acid)s as new co-formers in amorphous solid dispersion. Int. J. Pharm, 2023, 634:122645. (5)Zhiren Zou, Qiang Huang, Xiaobo Li, Xianzhi Liu, Lina Yin, Yunjie Zhao, Guang Liang, Wenqi Wu. Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization. Eur. J. Pharm. Sci., 2023, 188:106526.
|